Finance

Lists
Q2 2027 earnings • released • Revenue beat +1.92%
See results
4543:TYO
Terumo Corp
¥2,400.00
-6.18%
(-158.00) 1D
Nov 13, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4543...
Open
¥2,303
High
¥2,429
Low
¥2,280
Mkt. cap
3.55T
Avg. vol.
6.31M
Volume
13.59M
Dividend
1.25%
Quarterly dividend
¥8
Ex-dividend date
Sep 29, 2026
P/E ratio
21.53
52-wk high
¥2,689
52-wk low
¥1,900
EPS
¥111
Shares outstanding
370.59M
No. of employees
31K
Open
¥2,303
High
¥2,429
Low
¥2,280
Mkt. cap
3.55T
Avg. vol.
6.31M
Volume
13.59M
Dividend
1.25%
Quarterly dividend
¥8
Ex-dividend date
Sep 29, 2026
P/E ratio
21.53
52-wk high
¥2,689
52-wk low
¥1,900
EPS
¥111
Shares outstanding
370.59M
No. of employees
31K
News stories
From web sources and news partners
Profile
Terumo Corporation was founded in 1921 as Red Line Thermometer Corporation by a group of medical scientists led by Dr. Kitasato Shibasaburō to produce medical thermometers in Japan. The company's first product was "Jintan Taionkei", the first Japanese-made thermometer available for sale, and it has since expanded into a medical devices manufacturer, producing medical disposables, cardiovascular systems and diabetes care products. In 1971, Terumo opened its first overseas office in the United States. Since then, the company has established subsidiaries in Europe, South America, China, India, Philippines, Vietnam, Thailand, Australia and México. The company later expanded its product range to include coronary stents and catheters, and acquired, among others, the cardiovascular specialty companies Vascutek and Microvention in 2002 and 2006 respectively. Wikipedia
About Terumo Corp
CEO-
Employees31.2K
FoundedSep 17, 1921
HeadquartersShibuya, Tokyo, Japan
SectorHealth Care
IndustryMedical device
Websiteterumo.co.jp
Last report
Nov 12, 2026
Fiscal period
Q2 2027
- / -
Revenue / Est. (JPY)
312.69B / 306.80B
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
274.96B
296.63B
300.32B
311.81B
Cost of goods sold
127.97B
143.44B
149.06B
133.27B
Cost of revenue
127.97B
143.44B
149.06B
133.27B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
97.88B
105.26B
107.66B
109.70B
Operating expense
101.90B
109.31B
98.62B
89.06B
Total operating expenses
229.87B
252.74B
247.68B
222.33B
Operating income
45.10B
43.88B
52.64B
89.48B
Other non operating income
-1.00M
2.00M
-409.00M
-4.00M
EBT including unusual items
45.95B
45.38B
31.66B
90.32B
EBT excluding unusual items
45.95B
45.38B
52.86B
90.32B
Income tax expense
10.90B
12.72B
5.30B
19.89B
Effective tax rate
23.72%
28.04%
16.73%
22.03%
Other operating expenses
4.02B
4.05B
-9.05B
-20.64B
Net income
35.05B
32.65B
26.37B
70.43B
Net profit margin
12.75%
11.01%
8.78%
22.59%
Earnings per share
-
-
-
-
Interest and investment income
1.02B
2.21B
-
2.38B
Interest expense
-18.00M
-463.00M
-1.32B
-1.48B
Net interest expenses
1.00B
1.75B
-1.32B
905.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
66.76B
69.98B
79.07B
116.67B
Gain or loss from assets sale
4.72B
154.00M
188.00M
12.00M
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps